Annual Drug Patent Expirations for VRAYLAR
Vraylar is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.
Drug patent litigation for VRAYLAR.
This drug has one hundred and eight patent family members in forty-two countries.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. Two suppliers are listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
